Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

139.05USD
4:00pm EDT
Change (% chg)

$-0.45 (-0.32%)
Prev Close
$139.50
Open
$139.09
Day's High
$139.99
Day's Low
$137.91
Volume
2,351,862
Avg. Vol
1,998,136
52-wk High
$148.32
52-wk Low
$118.62

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $357,562.41
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.52

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.53 30.91 33.65
EPS (TTM): 5.91 -- --
ROI: 13.49 14.75 14.28
ROE: 22.63 16.25 16.00

Judge rejects J&J bid to move Illinois talc case to federal court

A federal judge in Illinois has rejected Johnson & Johnson's bid to transfer a lawsuit alleging its talc products caused a woman's ovarian cancer to federal from state court.

Oct 17 2018

J&J beats profit estimates, lifts outlook on pharma unit strength

Johnson & Johnson reported slightly better-than-expected third quarter profit and raised its full-year forecast on Tuesday as increased demand for cancer drugs and immune disorder treatments powered strong results for its pharmaceutical unit.

Oct 16 2018

J&J applauds U.S. proposal on drug prices in TV ads

Johnson & Johnson applauded a U.S. government proposal requiring drugmakers to include price of medicines in television ads, Chief Financial Officer Joseph Wolk said in a CNBC interview on Tuesday.

Oct 16 2018

UPDATE 3-J&J beats profit estimates, lifts outlook on pharma unit strength

* Sees device unit growing in-line or better than market by 2020 (Adds details from conference call, share move)

Oct 16 2018

CORRECTED-UPDATE 2-Johnson & Johnson edges past profit estimates, lifts outlook

Oct 16 Johnson & Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade.

Oct 16 2018

Johnson & Johnson quarterly profit rises 4.5 percent

Oct 16 Johnson & Johnson reported a 4.5 percent rise in quarterly profit on Tuesday and boosted its sales and earnings per share guidance, as rising sales of its cancer drugs Zytiga and Darzalex helped offset falling sales of blockbuster arthritis drug Remicade.

Oct 16 2018

Jury clears J&J of liability in New Jersey talc cancer case

A New Jersey jury on Thursday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer.

Oct 12 2018

Jury clears J&J of liability in New Jersey talc cancer case

Oct 11 A New Jersey jury on Thursday cleared Johnson & Johnson of liability in a case involving a woman who alleged that the company's talc-based products, including its baby powder, contain asbestos and caused her cancer.

Oct 11 2018

J&J's Acclarent seeks to escape whistleblower retaliation case

Johnson & Johnson unit Acclarent Inc says that a former sales representative cannot prove she was fired because she complained to her bosses about the company's promotion of a medical device for unapproved uses, rather than her poor performance.

Oct 10 2018

J&J's Stelara succeeds in chronic bowel disease study

Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.

Oct 09 2018

Earnings vs. Estimates